Page 1

FARON Faron Pharmaceuticals Oy ( " Faron " ) Faron Reports Half - Year Financials , January 1 - June 30 , 2021 Significant progress made in H1 2021 including acceleration of most advanced pipeline assets - Bexmarilimab and Traumakine® August 26 , 2021 at 7:00 am BST / 9:00 am EEST January - June 2021 in short / Summary of January - June 2021 Bexmarilimab shows compelling antitumor activity in multiple advanced solid tumor types as a monotherapy with strongest disease control rate , DCR ( 30.0 % - 40.0 % ) , observed in cutaneous melanoma , gastric cancer , cholangiocarcinoma and hepatocellular carcinoma patients Median overall survival ( OS ) not yet reached in DCR patient group Initiation of pivotal stage ( Part III ) of bexmarilimab's MATINS study on track for Q4 2021 alongside clinical expansion into neoadjuvant setting , hematological malignancies and first line lung cancer in combination with anti - PD - 1 ● ● Secured key US patents for both bexmarilimab and TraumakineⓇ Received $ 6.1 million commitment from the US Department of Defense ( DoD ) to support the Traumakine HIBISCUS trial as part of the Coronavirus Aid , Relief , and Economic Security ( CARES ) Act Balance sheet strengthened by successful share placing of € 15 million gross including investment from European Investment Council ( EIC ) Fund , a breakthrough initiative from the European Commission Virtual briefing and Q & A to be held today at 12:00 pm BST / 2:00 pm EEST / 7:00 am EDT TURKU , FINLAND / BOSTON , MA - Faron Pharmaceuticals Oy ( AIM : FARN , First North : FARON ) , a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation , today announced unaudited half - year financial results for January 1 to June 30 , 2021 ( the " period " ) and provided an overview of recent corporate developments . " I am extremely proud of the progress we made over the first half of 2021 , " said Dr. Markku Jalkanen , Chief Executive Officer of Faron . We progressed our most advanced pipeline assets with bexmarilimab showing compelling ant activity as a monotherapy in heavily pre - treated patients across multiple solid tumor types and the initiation of the HIBISCUS trial assessing Traumakine as a first - line treatment for hospitalized COVID - 19 patients , which we believe will represent a significant step forward in the treatment of lung failure due to viral infections . We also strengthened our balance sheet , which will allow us to continue investing in our pipeline and further our goal of developing new treatments for patients battling life - threatening diseases . " HIGHLIGHTS ( including post period ) : Pipeline Highlights Bexmarilimab - Faron's wholly - owned , novel precision cancer immunotherapy candidate , in Phase I / II development for difficult - to treat cancers . Compelling antitumor activity in multiple advanced solid tumor types was reported from patients enrolled in the completed Part I and ongoing Part II of the MATINS study , investigating bexmarilimab as a potential monotherapy in patients with solid tumors who have exhausted all treatment options . The strongest results were observed in cutaneous melanoma , gastric cancer , cholangiocarcinoma , and hepatocellular carcinoma , with a 30.0 % - 40.0 % disease control rate across these tumor types . Additional MATINS data was accepted as a late - breaking abstract and will be presented at the European Society for Medical Oncology ( ESMO ) Congress 2021 in mid - September . Further clinical trials are planned to start in Q4 2021 to investigate bexmarilimab's potential in additional clinical settings , including in combination with standard of care as a first - line therapy in selected advanced solid tumors and as a monotherapy in hematological malignancies . Additionally , trials will also investigate bexmarilimab as a standalone neoadjuvant therapy for patients with early - stage colorectal cancer and renal cell carcinoma . A key US patent with claims protecting the composition of matter of bexmarilimab was granted by the United States Patent and Trademark Office . The patent covers bexmarilimab's binding sequences and Clever - 1's corresponding